RecruitingPhase 1NCT06156410
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Studying Skeletal Ewing sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital of Philadelphia
- Principal Investigator
- Theodore Laetsch, MD, MDChildren's Hospital of Philadelphia
- Intervention
- Cabozantinib(drug)
- Enrollment
- 30 target
- Eligibility
- 5-40 years · All sexes
- Timeline
- 2023 – 2028
Study locations (4)
- University of California San Francisco, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
Collaborators
Children's Hospital Colorado · Alex's Lemonade Stand Foundation · Exelixis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06156410 on ClinicalTrials.govOther trials for Skeletal Ewing sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07188532Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR TrialMayo Clinic
- RECRUITINGPHASE2NCT06699472A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using TrilaciclibFudan University
- RECRUITINGPHASE1, PHASE2NCT06395103Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT05968768To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)Anna Raciborska